1 / 21

Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia ( TASTE trial)

UCR Uppsala Clinical Research Center. Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia ( TASTE trial). Ole Fröbert, MD, PhD - on behalf of the TASTE investigators Departement of Cardiology Örebro University Hospital Sweden. Main results at 30 days. Background.

hyacinth-everett
Download Presentation

Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia ( TASTE trial)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. UCR Uppsala Clinical Research Center Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE trial) Ole Fröbert, MD, PhD - on behalf of the TASTE investigators Departement of Cardiology Örebro University Hospital Sweden Main results at 30 days

  2. Background • Intracoronary thrombus aspiration may reduce distal embolization and improve reperfusion • No previous randomized trial on thrombus aspiration has been powered for hard endpoints • Current ESC recommendation: class IIa with a level of evidence B

  3. TAPAS / Swedish registry data PCI alone (N=16 417) TA+PCI (N=3 666) HR (95% CI): 1.21 (1.08-1.35) Vlaar, P.J. et al. The Lancet 2008; 371:1915-20 Fröbert, O. et al. Int J Cardiol. 2010; 145:572-3

  4. Methods (1) • All 29 Swedish, 1 Icelandic and 1 Danish PCI center • Inclusion criteria • STEMI and ability to provide oral consent • <24 h symptoms • correspondence between ECG and angio findings • Exclusion criteria • need for emergency CABG • age <18 years • previous randomization in TASTE • 1:1 randomization to manual thrombus aspiration and PCI vs. PCI alone

  5. Methods (2) • Endorsed aspiration catheters • Eliminate (Terumo), Export (Medtronic) and Pronto (Vascular Solutions) • Anticoagulation and platelet inhibition according to current guideline recommendations • Primary endpoint • time to all-cause death at 30 days • Secondary endpoints • time to rehospitalization with reinfarction at 30 days • time to stent thrombosis at 30 days

  6. Methods (3) • TASTE introduces the Registry-based Randomized Clinical Trial (RRCT) concept • Online health quality registries (SCAAR and SWEDEHEART) serve as on-line platforms for: • randomization • case record forms • follow-up

  7. TASTEtrial enrollment flow chart Enrolled in Denmark N=247 All patients with STEMI in Sweden and Iceland undergoing primary or rescue PCI. N=11 709 *) Enrolled in TASTE N=7259 Not enrolled N=4697 Erroneous enrollments N=15 Randomized in TASTE N=7244 No patients (0) were lost to follow-up of the primary endpoint! N=3621 assigned to thrombus aspiration N=3623 assigned to conventional PCI N=3399 underwent thrombus aspiration N=222 underwent conventional PCI N=3445 underwent conventional PCI N=178 underwent thrombus aspiration N=1162 underwent thrombus aspiration N=3535 underwent conventional PCI N=1162 were followed up N=3621 were followed up N=3623 were followed up N=3535 were followed up

  8. TASTE and previous studies TASTE

  9. Baselineclinicalcharacteristics

  10. Baselineproceduralcharacteristics

  11. Post randomizationcharacteristics (1) Glycoprotein Iib/IIIa inhibitor

  12. Post randomizationcharacteristics (2)

  13. All-cause mortality at 30 days HR 0.94 (0.72 - 1.22), P=0.63 Per protocol analysis based on actual treatment: HR 0.88 (0.66 - 1.17), P=0.38

  14. Reinfarction at 30 days HR 0.61 (0.34 - 1.07), P=0.09 Per protocol analysis based on actual treatment: HR 0.67 (0.36 - 1.20), P=0.19

  15. Additionalresults

  16. TASTE vs. TAPAS

  17. TASTE vs. TAPAS

  18. Conclusions • This large, prospective, registry-based randomized clinical trial showed: • no reduction of mortality at 30 days • no significant reduction of hospitalization for MI or of stent thrombosis at 30 days • no reduction of other important clinical endpoints during hospitalization • Our findings leave little role for manual thrombus aspiration as a routine adjunct to PCI in STEMI

  19. Steering committee • Michael Mæng, MD, PhD (DENMARK) • Thórarinn Gudnason, MD, PhD (ICELAND) • Ole Fröbert, MD, PhD (PI) • Stefan K. James, MD, PhD (chair) • Bo Lagerqvist, MD, PhD • Göran K. Olivecrona, MD, PhD Participating centers Karolinska Institutet, Södersjukhuset, Sweden. Karolinska Solna and Huddinge Hospitals, Sweden. Karolinska University Hospital, Sweden. Kristianstad Hospital, Sweden. Sahlgrenska University Hospital, Gothenburg, Sweden. Skövde Hospital, Sweden. Sunderby Hospital, Sweden. Sundsvall Hospital, Sweden. Trollhättan Hospital, Sweden. Umeå University Hospital, Sweden. Uppsala Clinical research center, Sweden. Västerås Hospital, Sweden. Örebro University Hospital, Sweden. Landspitali University Hospital, Reykjavik, Iceland. Aarhus University Hospital, Denmark. Borås Hospital, Sweden. Capio, S:t Görans Hospital, Sweden. Danderyd University Hospital, Sweden. Eskilstuna Hospital, Sweden. Falun Hospital, Sweden. Gävle Hospital, Sweden. Halmstad Hospital, Sweden. Helsingborg Hospital, Sweden. Jönköping Hospital, Sweden. Linköping University Hospital, Sweden. Lund University Hospital, Sweden. Malmö Hospital, Sweden. Kalmar Hospital, Sweden. Karlskrona Hospital, Sweden. Karlstad Hospital, Sweden.

More Related